P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability
| Autor: | Li, Wenlong, Sparidans, Rolf W., Wang, Yaogeng, Lebre, Maria C., Beijnen, Jos H., Schinkel, Alfred H. |
|---|---|
| Zdroj: | In Pharmacological Research November 2018 137:47-55 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect